Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gep Net”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03963193
What this trial is testing

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Who this might be right for
Gastrointestinal Neuroendocrine Tumor
Henan Cancer Hospital 112
Not applicableLooking for participantsNCT07635316
What this trial is testing

Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 4,023
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Large-scale testing (Phase 3)Looking for participantsNCT07185672
What this trial is testing

PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Gastroenteropancreatic Tumour
Tata Memorial Hospital 162
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Not applicableLooking for participantsNCT06155318
What this trial is testing

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
IRCCS San Raffaele 300
Not applicableLooking for participantsNCT06356467
What this trial is testing

Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs

Who this might be right for
Neuroendocrine TumorsGEP-NET
IRCCS San Raffaele 450
Not applicableLooking for participantsNCT06256705
What this trial is testing

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorRadiotherapy
Assistance Publique - Hôpitaux de Paris 80
Large-scale testing (Phase 3)Active Not RecruitingNCT03972488
What this trial is testing

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Advanced Accelerator Applications 226
Early research (Phase 1)Looking for participantsNCT06441331
What this trial is testing

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Who this might be right for
Somatostatin Receptor PositiveNETsLymphoma+5 more
ITM Solucin GmbH 20
Testing effectiveness (Phase 2)Ended earlyNCT01994213
What this trial is testing

Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 53
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Testing effectiveness (Phase 2)Ended earlyNCT05987176
What this trial is testing

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Who this might be right for
Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more
Imperial College London 1
Not applicableLooking for participantsNCT04949282
What this trial is testing

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Who this might be right for
Neuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Large-scale testing (Phase 3)Study completedNCT06091748
What this trial is testing

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 69
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Next Page